Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Link
http://www.nature.com/articles/1705627.pdf
Reference18 articles.
1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al., Intergroupe Français du Myélome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al., Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.
3. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052–3057 [E-pub 2004 Jul 20].
4. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al., Group Myelome-Autogreffe. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227–9233 [E-pub 2005 Nov 7].
5. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Renaud M et al. Major superiority of melphalan–prednisone (MP)+thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma (abstract). Blood 2005; 106: 230a.
Cited by 57 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Deciphering the metabolic heterogeneity of hematopoietic stem cells with single-cell resolution;Cell Metabolism;2024-01
2. The First 100-day Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients: Melphalan 200 mg/m² versus 140 mg/m² Conditioning Regimen;Turkish Journal of Clinics and Laboratory;2023-09-30
3. Kidney Disease Following Hematopoietic Stem Cell Transplantation;Advances in Chronic Kidney Disease;2022-03
4. Transgelin-2 in Multiple Myeloma: A New Marker of Renal Impairment?;Molecules;2021-12-23
5. Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma;Bone Marrow Transplantation;2020-08-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3